[8-K] abrdn Income Credit Strategies Fund Reports Material Event

Rhea-AI Filing Summary

Teva Pharmaceutical Industries Ltd. (TEVA) has filed a Form 144 announcing the possible sale of 52,742 ordinary shares through Citigroup Global Markets on or about 01-Aug-2025. The shares carry an estimated aggregate market value of $799,437 and equal roughly 0.005 % of the 1.15 billion shares outstanding, indicating a very small portion of the company’s float. The seller—an unnamed insider—received the stock on 01-Aug-2022 via a restricted share-unit (RSU) award. No other sales have been reported in the past three months. A Form 144 is a notice, not a guarantee, but signals that the insider may execute the transaction on the NYSE under Rule 144. Given the modest size and compensation-related origin, market impact is expected to be minimal, though insider sales can be perceived as a slight negative sentiment indicator.

Positive

• None.

Negative

• Insider plans to sell 52,742 shares worth approximately $0.8 M, which can be viewed as a slight negative sentiment signal.

Insights

Financial Analyst

TL;DR: Very small insider sale (~$0.8 M, 0.005 % float); signal mildly negative but fundamentally immaterial.

The filing reveals an insider’s intent to sell 52,742 RSU-derived shares. With 1.15 Bn shares outstanding, the sale is de minimis, unlikely to influence liquidity or price dynamics. Because the stock was earned via compensation and the insider has made no recent sales, the move could reflect routine diversification rather than concern over fundamentals. Investors may note it as a marginally bearish sentiment cue, yet the absence of additional negative disclosures or large volume keeps the overall impact neutral.

false 0001503290 0001503290 2025-08-01 2025-08-01 0001503290 ACP:CommonSharesOfBeneficialInterestMember 2025-08-01 2025-08-01 0001503290 ACP:Sec5.250SeriesPerpetualPreferredSharesLiquidationPreference25.00Member 2025-08-01 2025-08-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) August 1, 2025 (August 1, 2025)

abrdn Income Credit Strategies Fund

(Exact name of registrant as specified in its charter)

Delaware		811-22485		80-0660749
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)
1900 Market Street, Suite 200 Philadelphia, PA				19103
(Address of principal executive offices)				(Zip Code)

Registrants telephone number, including area code (800)-522-5465

(Former name or former address, if changed since last report.) 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:  

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Shares of Beneficial Interest	ACP	New York Stock Exchange
5.250% Series A Perpetual Preferred Shares (Liquidation Preference $25.00)	ACP PRA	New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

¨ Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨   

Item 1.01. Entry into a Material Definitive Agreement.

On August 1, 2025, abrdn Income Credit Strategies Fund (NYSE: ACP) (the “Fund”) entered into a distribution agreement (the “Distribution Agreement”) with ALPS Distributors, Inc. (the “Distributor”), pursuant to which the Fund may offer and sell up to $75,000,000 of common shares of beneficial interest, par value $0.001 per share (“Common Shares”), from time to time through the Distributor, in transactions deemed to be “at the market” as defined in Rule 415 under the Securities Act of 1933, as amended (the “Offering”). Under the Investment Company Act of 1940, as amended, the Fund may not sell any Common Shares at a price below the current net asset value of such common shares, exclusive of any distributing commission or discount.

Pursuant to the Distribution Agreement, the Distributor may enter into sub-placement agent agreements with one or more selected dealers. The Distributor has entered into a sub-placement agent agreement, dated August 1, 2025 (the “Sub-Placement Agent Agreement”), with UBS Securities LLC (the “Sub-Placement Agent”) relating to the Common Shares to be offered under the Distribution Agreement.

The Offering is being made pursuant a prospectus supplement, dated August 1, 2025 and the accompanying prospectus, dated May 30, 2024, each of which constitute part of the Fund’s effective shelf registration statement on Form N-2 (File No. 333-277607) previously filed with the Securities and Exchange Commission (the “Registration Statement”).

The foregoing descriptions of the Distribution Agreement and the Sub-Placement Agent Agreement do not purport to be complete and are qualified in their entirety by reference to the full text of the Distribution Agreement filed with this report as Exhibit 1.1 and incorporated herein by reference, and the full text of the Sub-Placement Agent Agreement filed with this report as Exhibit 1.2 and incorporated herein by reference.

Item 8.01. Other Events

On August 1, 2025, the Fund commenced the Offering pursuant to the Fund’s Registration Statement. A copy of the opinion of Dechert LLP relating to the legality of the Common Shares is filed as Exhibit 5.1 to this report.

The Fund incorporates by reference the exhibits filed herewith into the Registration Statement.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

	1.1	Distribution Agreement between the Registrant and ALPS Distributors, Inc.
	1.2	Sub-Placement Agent Agreement between ALPS Distributors, Inc. and UBS Securities LLC
	5.1	Opinion of Dechert LLP
	23.1	Consent of Dechert LLP (included in Exhibit 5.1)
	104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	abrdn Income Credit Strategies Fund
Date: August 1, 2025	By:	/s/ Robert Hepp
	Name:	Robert Hepp
	Title:	Vice President

FAQ

How many TEVA shares are being sold under this Form 144?

The insider intends to sell 52,742 ordinary shares.

What is the estimated market value of the proposed TEVA share sale?

The aggregate market value is approximately $799,437.

What percentage of TEVA’s outstanding shares does the sale represent?

Roughly 0.005 % of the 1.15 billion shares outstanding.

When were the shares originally acquired by the insider?

The shares were acquired on 01-Aug-2022 via a restricted share-unit award.

Which broker will handle the TEVA share sale and on which exchange?

The sale is to be executed through Citigroup Global Markets on the NYSE.